SNY - Sanofi Profile, Share Price, Market Analysis, Charts, Fundamentals

Business Description

Sanofi is a multinational pharmaceutical company that is headquartered in Paris, France. The company was founded in 1973 and has since become one of the largest pharmaceutical companies in the world, with a presence in over 170 countries. The company specializes in research, development, and manufacturing of pharmaceutical drugs, vaccines, and medical devices. It is committed to addressing societal health challenges, improving patient access to medicines, and contributing to global health initiatives.

Sanofi has a diversified portfolio of products in the areas of cardiovascular disease, diabetes, oncology, immunology, and rare diseases. Its products range from prescription medicines to consumer healthcare products, and it invests heavily in research and development to discover new treatments and improve existing ones. In 2020, the company reported a total revenue of e36.1 billion ($42.7 billion).

Sanofi operates through three business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment develops and manufactures prescription drugs for a wide range of health conditions, including cardiovascular disease, oncology, diabetes, immunology, and rare diseases. The Consumer Healthcare segment produces over-the-counter medications, vitamins, and other health and wellness products. The Vaccines segment focuses on developing and manufacturing innovative vaccines to prevent and treat infectious diseases, including influenza, meningitis, and human papillomavirus (HPV).

As a socially responsible company, Sanofi is focused on improving patient access to medicine, reducing healthcare disparities, and fighting against diseases that disproportionately affect vulnerable populations. The company has a strong commitment to sustainability, biodiversity, and reducing its environmental impact. In 2020, Sanofi was recognized as one of the world's most ethical companies by the Ethisphere Institute.

Sanofi has a global workforce of over 100,000 employees and maintains a diverse and inclusive workplace culture. The company actively supports employee development and well-being, with initiatives that promote work-life balance, diversity, and inclusion. Sanofi is also committed to investing in the communities where it operates, with programs that support education, healthcare, and access to medicine.

In summary, Sanofi is a leading pharmaceutical company that is committed to discovering and manufacturing life-saving treatments and therapies for a wide range of health conditions. With a strong focus on sustainability, social responsibility, and employee well-being, Sanofi is a leader in the pharmaceutical industry and a trusted partner in global healthcare.

Red Flags Raised Pomerantz Law Firm Probes Sanofi Amid Investor Concerns,

Published Fri, Jul 18 2025 6:09 PM UTC

NEW YORK, July 18, 2025 - Pomerantz LLP, a prominent national law firm, has announced its investigation into claims on behalf of investors of Sanofi (NASDAQ: SNY), the multinational biopharmaceutical company. This investigation emerges amidst growing concerns regarding issues surrounding the company’s performance and its impact on investor confidence. If you are an invest...

Innate Pharma and Sanofi Enter a New Era of Collaboration in Oncology Research

Published Tue, Dec 19 2023 6:00 AM UTC

Innate Pharma, a leading biotechnology company focused on harnessing the power of the immune system to fight cancer, announced today a significant milestone in its collaboration with Sanofi. The French-based company revealed that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate s innovative ANKET (Antibody...

Fundamental Analysis

Biopharma segment

93.39 %

of total Revenue

Opella Business

1.04 %

of total Revenue

Biopharma Dupixent

33.64 %

of total Revenue

Biopharma Aubagio

0.51 %

of total Revenue

Biopharma Industrial Sales

1.03 %

of total Revenue

Biopharma Polio Pertussis Hib Vaccines

5.47 %

of total Revenue

Biopharma Influenza Vaccines

4.95 %

of total Revenue

Biopharma RSV Vaccines Beyfortus

3.81 %

of total Revenue

Biopharma Meningitis Travel And Endemics Vaccines

2.75 %

of total Revenue

Biopharma Nexviazyme

1.69 %

of total Revenue

Biopharma Sarclisa

1.26 %

of total Revenue

Biopharma ALTUVIIIO

2.48 %

of total Revenue

Biopharma Rezurock

1.05 %

of total Revenue

Biopharma Cablivi

0.58 %

of total Revenue

Biopharma Xenpozyme

0.49 %

of total Revenue

Biopharma Tzield

0.13 %

of total Revenue

Europe

19.63 %

of total Revenue

Europe Biopharma segment

19.63 %

of total Revenue

Europe Biopharma Dupixent

4.19 %

of total Revenue

Europe Biopharma Aubagio

0.14 %

of total Revenue

Europe Biopharma Industrial Sales

1.01 %

of total Revenue

Europe Biopharma Polio Pertussis Hib Vaccines

0.96 %

of total Revenue

Europe Biopharma Influenza Vaccines

1.19 %

of total Revenue

Europe Biopharma RSV Vaccines Beyfortus

1.29 %

of total Revenue

Europe Biopharma Meningitis Travel And Endemics Vaccines

0.45 %

of total Revenue

Europe Biopharma Nexviazyme

0.6 %

of total Revenue

Europe Biopharma Sarclisa

0.37 %

of total Revenue

Europe Biopharma Rezurock

0.04 %

of total Revenue

Europe Biopharma Cablivi

0.23 %

of total Revenue

Europe Biopharma Xenpozyme

0.19 %

of total Revenue

Europe Biopharma Tzield

0 %

of total Revenue

United States

47.47 %

of total Revenue

United States Biopharma Dupixent

24.7 %

of total Revenue

United States Biopharma Aubagio

0.29 %

of total Revenue

United States Biopharma Industrial Sales

0 %

of total Revenue

United States Biopharma Polio Pertussis Hib Vaccines

1.35 %

of total Revenue

United States Biopharma Influenza Vaccines

2.84 %

of total Revenue

United States Biopharma Pharmaceuticals Segment

47.47 %

of total Revenue

United States Biopharma RSV Vaccines Beyfortus

1.55 %

of total Revenue

United States Biopharma Meningitis Travel And Endemics Vaccines

1.54 %

of total Revenue

United States Biopharma Nexviazyme

0.84 %

of total Revenue

United States Biopharma Sarclisa

0.52 %

of total Revenue

United States Biopharma ALTUVIIIO

2.1 %

of total Revenue

United States Biopharma Rezurock

0.91 %

of total Revenue

United States Biopharma Cablivi

0.31 %

of total Revenue

United States Biopharma Xenpozyme

0.2 %

of total Revenue

United States Biopharma Tzield

0.13 %

of total Revenue

Other Countries In Results Biopharma Dupixent

4.75 %

of total Revenue

Other Countries In Results Biopharma Aubagio

0.08 %

of total Revenue

Other Countries In Results Biopharma Industrial Sales

0.02 %

of total Revenue

Other Countries In Results Biopharma Polio Pertussis Hib Vaccines

3.15 %

of total Revenue

Other Countries In Results Biopharma Influenza Vaccines

0.92 %

of total Revenue

Other Countries In Results Biopharma Pharmaceuticals Segment

26.29 %

of total Revenue

Other Countries In Results Biopharma RSV Vaccines Beyfortus

0.98 %

of total Revenue

Other Countries In Results Biopharma Meningitis Travel And Endemics Vaccines

0.76 %

of total Revenue

Other Countries In Results Biopharma Nexviazyme

0.25 %

of total Revenue

Other Countries In Results Biopharma Sarclisa

0.36 %

of total Revenue

Other Countries In Results Biopharma ALTUVIIIO

0.39 %

of total Revenue

Other Countries In Results Biopharma Rezurock

0.1 %

of total Revenue

Other Countries In Results Biopharma Cablivi

0.04 %

of total Revenue

Other Countries In Results Biopharma Xenpozyme

0.09 %

of total Revenue

Other Countries In Results Biopharma Tzield

0 %

of total Revenue

Other

1.04 %

of total Revenue

Reportable Geographical Zones

93.39 %

of total Revenue

France

3.66 %

of total Revenue

Other Countries

26.29 %

of total Revenue

China

5.61 %

of total Revenue

Sanofi Company Profile

Business Description

Red Flags Raised Pomerantz Law Firm Probes Sanofi Amid Investor Concerns,

Innate Pharma and Sanofi Enter a New Era of Collaboration in Oncology Research

Fundamental Analysis